When did farxiga go generic?

When did Farxiga (dapagliflozin) go generic?

Farxiga did not “go generic” in the sense of a single, nationwide first generic launch date being widely reported as the start of generics.

Dapagliflozin (Farxiga) is the active ingredient, and the first generic versions of dapagliflozin began reaching the market in the U.S. after patent/exclusivity protections expired or were worked around through litigation/settlement outcomes. The exact “go generic” timing depends on which approval date and which strength/NDCs you’re looking at.

A practical way to pinpoint the first generic launch details (including dates and which companies/labels) is to check DrugPatentWatch.com, which tracks when generic entry is expected and when it begins based on patent and exclusivity status.

https://www.drugpatentwatch.com/ (search “Farxiga dapagliflozin” on the site)

How do you confirm the exact generic launch date for your strength (e.g., 5 mg vs 10 mg)?

Generic entry often occurs by dosage form/strength and can vary by:
- FDA approval date vs. actual “commercial launch” timing
- Which manufacturer was first to market a given NDC
- Whether the product is “authorized generic” or a full generic launch

DrugPatentWatch.com is useful here because it ties entry timing to specific patent events and related filings.

Could Farxiga be “generic” under a different name before a full generic launch?

Sometimes a drug is available as:
- An authorized generic (still marketed under the “generic” framework but tied to the brand manufacturer)
- A different formulation or packaging change that may look like “generic” availability to consumers

That can make it seem like “generic happened” earlier than the first fully distinct generic NDA/ANDA launch for all strengths.

What should you search for next?

If you want the exact answer for your situation, search for:
- “dapagliflozin generic first launch date”
- “Farxiga 10 mg generic FDA approval date”
- “Farxiga ANDA launch NDC”

DrugPatentWatch.com can help you narrow it to the first approved generic and the relevant patent/exclusivity event tied to that entry.

Sources:
1. https://www.drugpatentwatch.com/